Cardiol Therapeutics (CRDL) Other Non-Current Liabilities (2020 - 2026)

Cardiol Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (changed N/A YoY) and the FY2023 annual result came in at $2.6 million, changed 0.29% from the prior year.
• Other Non-Current Liabilities was $2.1 million for Q1 2026 at Cardiol Therapeutics, down from $2.6 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $4.3 million in Q2 2022 and bottomed at $2.1 million in Q1 2026.
• A 4-year average of $2.9 million and a median of $2.6 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities climbed 4.79% — and 2023, when it plunged 39.65%.
• Cardiol Therapeutics' Other Non-Current Liabilities stood at $2.6 million in 2022, then dropped by 0.29% to $2.6 million in 2023, then advanced by 1.03% to $2.6 million in 2024, then dropped by 21.23% to $2.1 million in 2026.
• Business Quant data shows CRDL's Other Non-Current Liabilities at $2.1 million in Q1 2026, $2.6 million in Q1 2024, and $2.6 million in Q4 2023.